Invivyd Inc (IVVD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.63+8.96%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · IVVD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -75.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 41.2% |
Growth built into the price is above our model estimate.
The price assumes 117.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
IVVD — CEO transition
Dated 2026-09-01
CEO — Marc Elia: The filing discloses the appointment of the Board Chairman as CEO, an internal succession event rather than a departure of a sitting executive.
Why it matters: PEMGARDA revenue is growing, but the FDA gave notice that its EUA may end. A revenue decline could add pressure while VYD2311 moves through review.
Watch forQuarterly PEMGARDA revenue stays at or above $14.3 million. FDA talks support access past June 29, 2027.
Also watch forQuarterly PEMGARDA revenue falls below $14.3 million, or the FDA confirms the EUA will end on June 29, 2027.
Why it matters: The data are the main test of whether VYD2311 can move toward an FDA filing. A filing plan still depends on supportive safety and antibody data.
Watch forInvivyd reports safety and antibody data from DECLARATION. The data support its BLA plan. It reports no major safety issue.
Also watch forThe data show a major safety concern or antibody levels that miss the target profile. Invivyd delays or drops its BLA plan.
Why it matters: Invivyd had $160.1 million in cash at June 30, 2026. The company said it could fund the trial readout and launch preparation, but costs remain high.
Worry ifCash falls below $160.1 million before a VYD2311 filing, while quarterly net loss stays above $44.4 million.
Less concerning ifCash stays at or above $160.1 million through the filing, or reported losses fall below $44.4 million per quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$399 on $10,000 · ±4.0% | How much price usually moves either way. |
| Bad day | $899 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,142 loss on $10,000 · 81.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.